Saturday, July 11, 2026

Drug profile · INN

dabigatran etexilate methanesulfonate

dabigatran etexilate methanesulfonate (PRADAXA) is an FDA-listed pharmaceutical active ingredient.

PMDA: approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — dabigatran etexilate methanesulfonate
Class
Route
Patents
0
Programs
1
Data quality
0.78

Quick answer

dabigatran etexilate methanesulfonate (PRADAXA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN dabigatran etexilate methanesulfonate
Brand PRADAXA

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. Ticagrelor followed with Methoxyflurane Approved · COLLEGIUM PHARMACEUTICAL · Unstable Angina

Frequently asked questions

What is dabigatran etexilate methanesulfonate?

dabigatran etexilate methanesulfonate (PRADAXA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for dabigatran etexilate methanesulfonate?

PRADAXA is a marketed brand name for dabigatran etexilate methanesulfonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.